Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Catalent Pharma Solutions LLC has 1 pending office action currently active. This matter is assigned to 1 distinct examiner, CHI, AMANDA LYNN, who is the busiest examiner. With 0 distinct art units reported, the company's current patent activity is concentrated under a single examiner's evaluation. This singular focus means the company's immediate patent outcomes are tied directly to the review of this specific examiner. Practitioners should focus on the individual preferences of the assigned examiner to advance the 1 pending office action toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
| LU, CHENG | 1 | 54.1% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849392 | LIQUID FORMULATIONS OF IVERMECTIN COMPOSITIONS AND USE IN GELATIN DOSAGE FORMS | CHI, AMANDA LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849392 | LIQUID FORMULATIONS OF IVERMECTIN COMPOSITIONS AND USE IN GELATIN DOSAGE FORMS | CHI, AMANDA LYNN | — | §103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18532395 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | LU, CHENG | 1642 | §103 | Non-Final OA | — | Pending | Dec 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial